Bolt Biotherapeutics (BOLT) will host a key opinion leader conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalation clinical study of BDC-3042 that were presented at the American Associates for Cancer Research Annual Meeting that took place in April 2025. In addition, Bolt’s management team will discuss BDC-3042 partnering plans, present an update on BDC-4182 clinical development, and provide an update on first quarter 2025 financial results. A live Q&A will follow the prepared remarks.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting
- Cautious Hold Rating for Bolt Biotherapeutics Amidst Promising Developments and Uncertainties
- Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
- Bolt Biotherapeutics price target lowered to $1.25 from $1.50 at Stifel
- Cautious Hold Rating for Bolt Biotherapeutics Amid Uncertain Clinical and Financial Outlook